Comparing peptide manufacturers starts with the actual production site and the type of order: research synthesis, development material or a commercial API. A US sales address does not identify the synthesis location. This guide compares specific facility disclosures and shows how to use them without turning a company description into a verified batch result.
Which US peptide manufacturing facilities have specific public descriptions?
| Company and site | What the company's source describes | How to use the information | Primary source |
|---|---|---|---|
| Bachem, Torrance, California | Peptide new-chemical-entity development, solid-phase synthesis and small-to-medium-scale API production; the site page also lists non-GMP small-scale work. | Identify the production service and quality scope for the requested order rather than assigning one grade to everything the company supplies. | Torrance site description |
| PolyPeptide, Torrance, California | A facility described for mid- and large-scale solid-phase GMP peptide production, with development and purification capabilities. | Compare the synthesis and purification scope with the project's production stage and scale. | US site descriptions |
| PolyPeptide, San Diego, California | GMP clinical material and research peptide work, with research quantities from milligrams to grams described separately. | The same company can supply different material categories from different production programs. | US site descriptions |
| CPC Scientific, Rocklin, California | The current locations page identifies the Rocklin address. A November 24, 2025 update describes a 41,000-square-foot facility build-out for clinical-to-commercial peptide API production. | Distinguish a published construction update from evidence that a specific requested production line is commissioned and available. | Locations and dated construction update |
These are selected facility disclosures checked on October 3, 2026, not a ranking of ten suppliers or a census of every US peptide facility. The source column identifies company statements. It does not document an independent facility audit, a purchase, a tested lot or a quoted price.
Why company count and facility count differ
The two PolyPeptide rows describe two sites of one company. Bachem's company history records the acquisition of American Peptide Company in 2015. Listing the old company name as a separate current competitor can therefore double-count a historical business rather than add an independent option. Bachem's history supplies the ownership event; the relevant current site page supplies the facility capabilities.
CPC's locations page distinguishes Rocklin and Milpitas in California from Hangzhou in China. A company's US presence alone does not locate every order. For a meaningful comparison, the production location belongs beside the exact service and material specification.
Match the source to the type of order
| Order question | Useful comparison input | Evidence that answers it |
|---|---|---|
| Can this site synthesize the sequence? | Sequence length, modifications, required quantity and synthesis platform | Site capabilities and a project-specific technical proposal |
| What material category will be supplied? | Research synthesis, development material or API supply | Order specification and stated production program |
| What was measured in this lot? | Identity, chromatographic result and the other requested analytical tests | The lot-specific report and methods, rather than a company-wide marketing claim |
| What is the actual delivered cost? | Quantity, analytical package, purification, delivery time and shipping | A dated quote for the same scope across suppliers |
| Where will production occur? | The named synthesis, purification and release sites | Order-specific facility identification, rather than the sales office address |
This comparison keeps unlike services out of the same score. A small research order and a commercial API project have different specifications, lead times and documentation. Without comparable quotes and batch reports, a numerical quality or price ranking would conceal those differences.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →What does a peptide COA actually let you compare?
Identity, chromatographic purity and peptide content answer separate analytical questions. A purity percentage needs its method and reporting basis. A mass or sequence identity result addresses whether the expected molecule was detected. The stated vial weight can include counterions and water. None of these fields can substitute for every other field. Bachem's technical FAQ separately defines HPLC purity and net peptide content.
| Field | Question it addresses | Comparison detail |
|---|---|---|
| Lot number | Which production material does the report describe? | Match the report to the supplied lot. |
| Identity result | Does the measured molecule match the intended identity? | Compare the method and observed result with the intended peptide. |
| Chromatographic purity | How was the sample separated and the result expressed? | Retain the method and reporting basis beside the percentage. |
| Peptide content, counterions and water | How is the stated material mass accounted for? | Keep content distinct from chromatographic peak-area purity. |
| Additional analytical tests | Which requested measurements were performed? | Use the actual reported test results and specifications for that order. |
Frequently asked questions
Is there a verified best US peptide manufacturer?
The selected public sources describe facilities and services. They do not provide a comparable independent test of every supplier or a quality ranking for a particular sequence and lot.
Is American Peptide Company a separate current option from Bachem?
Bachem's history records its acquisition in 2015. Historical company names should be reconciled with current ownership and facility records before counting independent options.
Does a US office prove US synthesis?
No. The production site for the particular order is a different fact from the location of a sales office. CPC's published locations illustrate why site-level information matters.
Why is CPC's Rocklin update dated?
The November 2025 source describes construction. Its date and wording help distinguish the announced project from a statement about the availability of a particular production line today.
Primary sources used for the facility comparison
- Bachem Torrance, selected site capabilities.
- Bachem company history, American Peptide Company acquisition.
- PolyPeptide US sites, Torrance and San Diego.
- CPC locations and November 2025 Rocklin construction update.
Legal and Regulatory Landscape for US Peptide Buyers
This area has changed materially since 2023 and most listicle pages have not updated their guidance.
- FDA issued guidance in 2023 and updated in 2024 adding several commonly sold peptides to the list of bulk drug substances that cannot be used in 503A compounding. This list has included BPC-157, TB-500 (thymosin beta-4), and others. Check the current FDA 503A and 503B bulk drug substance lists at FDA.gov before assuming a peptide is legally compoundable.
- Research-use-only (RUO) peptides exist in a regulatory gray zone. Selling a peptide labeled RUO while implicitly marketing it for human use is an FTC violation and can constitute unauthorized drug promotion under FDA rules. Several enforcement letters have been issued in this space.
- WADA prohibits several peptide classes (growth hormone secretagogues, IGF-1 analogs, SARMs) in competitive sports regardless of legal purchase status. Athletes should check the current WADA prohibited list.
- State pharmacy boards independently regulate compounding. Even if FDA permits a substance federally, state boards may impose additional restrictions.
Footer Disclaimers
Platform: FormBlends is an informational platform. Content is produced for educational purposes and does not constitute medical advice, diagnosis, or treatment recommendation.
Research Compound Notice: Several peptides referenced on this page are sold for research purposes only and are not approved by the FDA for human use. Their inclusion in this guide does not imply endorsement of their use in humans outside of a licensed clinical or pharmaceutical context.
Results Disclaimer: No product quality claim on this page implies any particular clinical or experimental result. Peptide purity and manufacturing quality are necessary but not sufficient conditions for research or clinical efficacy.
Trademark Disclaimer: All manufacturer names, brand names, and trademarks mentioned on this page are the property of their respective owners. FormBlends has no affiliation with, and has received no compensation from, any manufacturer listed on this page. Rankings reflect editorial judgment based on publicly available information only.
Related peptide guides
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →